Online retailer Boohoo (LON: DEBS) is starting to improve its performance, but there is a long way to go. In the six months to August 2025, revenues fell from £385.4m to £296.9m, but there was a swing from an adjusted loss of £9.2m to an operating profit of £1.8m. There was still a pre-tax loss. Cost savings have been made and a full year pre-tax loss of £11.5m is forecast. Net debt should start to decline. There is a new incentive scheme for executives. Chief executive Dan Finley could be paid £148.1m if the share price reaches 300p within five years. Goldman Sachs has raised its share price target for the online retailer from 16p to 17p, but still says sell, while Barclays has cut its target from 13p to 11p and remains underweight. Despite this, the share price soared 104% to 23p.
European Metals Holdings (LON: EMH) joint venture Geomet has secured a €360m grant for the Cinovec lithium and tin project in the Czech Republic. This is Europe’s most advanced lithium project. EMH owns 49% of Geomet, which is expected to publish a definitive feasibility study soon. Zeus has modelled a 25-year mine life and an NPV10 of $1.04bn. Zeus has a fair value share price of 75p. The share price jumped 92.7% to 21.2p.
Lung imaging technology developer Polarean Imaging (LON: POLX) has signed a distributor agreement with DK Healthcare in South Korea. It has also won an order from the National Taiwan University Hospital for a Xenon MRI research system through its partner Philips. Polarean Imaging is asking for shareholder approval to leave AIM at a general meeting on 15 December. Even so, the share price recovered 47.1% to 0.125p, which is well below the 0.4p prior to the announcement of a strategic review.
Tanfield Group (LON: TAN) says the US courts have granted a motion for partial summary judgement in the dispute over Snorkel International, where Tanfield has a 49% stake that is the subject of a call option by the other shareholder. This summary judgement says that the 49% stake cannot be acquired for nil as the partner wanted to. A valuation plus interest will be calculated. The trial will begin in October. The share price increased 40.1% to 6.725p.
FALLERS
Syngas technology provider Eqtec (LON: EQT) has total debt of £6.1m and requires more cash for working capital. Major shareholder Rebel Ion may end up acquiring the £5.1m loan and the £700,000 convertible loan, which will be immediately converted. There is a standstill agreement with the existing lenders of the £700,000 convertible loan and this lasts until the end of the year. Existing shareholders may be offered the chance to acquire part of the debt. Discussions continue. The share price declined 37.1% to 0.11p.
Security technology supplier Thruvision (LON: THRU) grew interim revenues 36% to £2.6m, even though retail revenues were lower. Cash was £2.1m at the end of September 2025. The second half will be tougher than expected and Allenby has reduced its full year revenues forecast from £8m to £5m, while the loss is raised from £2.21m to £3.55m. There will still be cash by the end of March 2026. Herald has sold its 8.89% stake and Dr Graham Cooley has raised his shareholding from 6.8% to 7.02%. The share price is one-third lower at 0.55p.
Premier African Minerals (LON: PREM) has raised £500,000 at 0.0575p/share. This will be invested in the processing plant for the Zulu lithium and tantalum project. The share price dipped 32.4% to 0.0575p.
CelLBxHealth (LON: CLBX) raised £6.8m at 1p/share and could raise up to £1m more from a retail offer closing on 1 December. A capital reorganisation will reduce the nominal value of the shares so that they can be issued at this price. There will be £1.9m spent on R&D, £1m for sales and market and £1.2m for reorganisation and IT systems. The cancer diagnostics company will progress partnerships and reduce annual operating costs by more than £5.9m. Ther will also be development of additional assays for the Parsortix platform. The share price slid 30.9% to 1.175p.